加强制药行业的分析发展:用于虚拟方法可操作设计区域评估的DOE-QSRR模型
Paula Beatriz Silva Passarin1, Felipe Rebello Lourenço1
1Faculty of Pharmaceutical Sciences, Department of Pharmacy, University of São Paulo, Avenida Professor Lineu Prestes 508, Butantan, São Paulo, SP, Brazil.
开发了一种in silico工具,用于进行虚拟实验设计,用于分析类抗生素. 该工具有助于开发染色学方法,通过虚拟可操作区域确保可靠的结果.
科学领域:
- 分析化学 分析化学
- 制药科学 制药科学
- 计算化学计算化学
背景情况:
- 制药行业越来越多地采用了通过设计的分析质量 (AQbD) 方法.
- 开发强大的色谱方法用于类抗生素对质量控制至关重要.
研究的目的:
- 为虚拟实验设计 (DoE) 开发一个in silico工具,以帮助AQbD实施.
- 促进对类抗生素的染色学方法的开发.
主要方法:
- 为虚拟DoE开发一个in silico工具的开发.
- 使用实验设计对塞法莱克辛,塞法索林,塞福塔克西姆和塞夫特里亚克森的分析.
- 实验设计-量化结构-保留关系 (DOE-QSRR) 模型的推导和蒙特卡洛方法的应用.
- 使用独立数据验证DOE-QSRR模型和虚拟DOE.
- 对实验MODR进行虚拟多个最佳设计区域 (MODR) 的构建和验证.
主要成果:
- 能源部-QSRR模型实现了84.72%的确定系数.
- 虚拟DoE显示了超过77%的准确性.
- 经验证的虚拟MODR显示与实验MODR重叠超过84%.
- 在各种条件下,in silico工具有效地表明了分析物的趋势.
结论:
- 开发的in silico工具适用于指导对类的染色学方法的分析开发.
- 该工具允许具有足够自信的虚拟DOE实现足够的结果质量.
- 该工具生成的虚拟MODR是实验结果的可靠预测器.
更多相关视频
00:05In Silico Modeling Method for Computational Aquatic Toxicology of Endocrine Disruptors: A Software-Based Approach Using QSAR Toolbox
Published on: August 28, 2019
10:37Procedure to Evaluate the Efficiency of Flocculants for the Removal of Dispersed Particles from Plant Extracts
Published on: April 9, 2016
相关概念视频
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Drug Discovery: Overview
Response Surface Methodology
The process of RSM involves several key steps:
Analysis of Population Pharmacokinetic Data
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
